Simulation Software Market is Anticipated to Expand at an Impressive 11.83% CAGR through 2031 | SkyQuest Technology

Westford, USA, Nov. 18, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Simulation Software Market will attain a value of USD 40.5 Billion by 2031, with a CAGR of 11.83% over the forecast period (2024-2031). Advancements in simulation technology and growing demand for rapid prototyping and simulation are projected to bolster demand for simulation software […]

Verde Reports up to 13,944 ppm TREO 5,222 ppm MREO and 213 ppm DyTb

SINGAPORE, Nov. 18, 2024 (GLOBE NEWSWIRE) — Verde AgriTech Ltd (TSX: “NPK“) (OTCQX: “VNPKF“) (“Verde” or the “Company“) is pleased to announce significant drilling results from Alto da Serra target, one of the three targets of the Man of War project. Building on previously announced results from two other targets, Verde has completed the reassaying

Bitdeer Reported Unaudited Financial Results for the Third Quarter of 2024

SINGAPORE, Nov. 18, 2024 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company“), a world-leading technology company for blockchain and high-performance computing, today released its unaudited financial and operational results for the third quarter ended September 30, 2024. Q3 2024 Financial Highlights Total revenue was US$62.0 million, compared to US$87.3 million in

NewGenIvf Enters into a Binding Term Sheet with White Lion Capital for $100 Million Equity Line of Credit, Expandable to $500 Million

BANGKOK, Nov. 18, 2024 (GLOBE NEWSWIRE) — NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), today announced that it has entered into a binding term sheet (the “Term Sheet”) with White Lion Capital, LLC, (“White Lion”) a California-based institutional investor focused on high-growth, early-stage public companies, setting out the principal terms and conditions for

Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements

– 52-week LUNA data combined with follow-up from OPTIC at 4 years continue to support long-term potential best-in-class product profile of Ixo-vec – 6E10 dose in LUNA maintains visual and anatomic endpoints and demonstrates potential best-in-class injection-free rates and reduction in injection burden – No LUNA patients who received local steroid prophylaxis had inflammation at

GigaCloud Technology Inc Ranked No. 1 on Forbes’ List of ‘America’s Most Successful Small-Cap Companies 2025’

EL MONTE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) — GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B technology solutions for large parcel merchandise, today announced it has been ranked #1 on Forbes’ list of “America’s Most Successful Small-Cap Companies 2025,” an evaluation of over 900 companies with market

Canoo Partners with Northside Truck & Van to Deliver its Initial Parts Network and Reliable Service, Maintenance, and Repair Services to Customers in the United Kingdom

JUSTIN, Texas and LONDON, Nov. 18, 2024 (GLOBE NEWSWIRE) — Canoo Inc. (Nasdaq: GOEV), a high-tech advanced mobility company, today announced a new service, maintenance, and repair (SMR) agreement with Northside Truck & Van Ltd. (“Northside”), a premier automotive service provider in the United Kingdom. With a current aftersales portfolio of over 280 garages in

Asante Announces Closing of Second Tranche of US$100 Million Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 18, 2024 (GLOBE NEWSWIRE) — Asante Gold Corporation (CSE: ASE | GSE: ASG | FRANKFURT: 1A9 | U.S.OTC: ASGOF) (“Asante” or the “Company”) is pleased to announce that on Friday, November 15, 2024, the Company closed the

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

– CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – – Compelling clinical responses observed in lupus and myositis patients with up to six months of follow-up; first SSc patient demonstrated an emerging, drug-free

Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences

SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that it will participate in the following upcoming healthcare investment conferences: Evercore HealthCONx Conference (Miami)Fireside chat, Tuesday, December 3, 2:10 pm ET + 1×1 meetings Citi

Scroll to Top